NRX Pharmaceuticals Files 2024 Annual Report Amendment
Ticker: NRXPW · Form: 10-K/A · Filed: Apr 30, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 10-K/A |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
TL;DR
NRXP filed its 2024 10-K amendment on 4/30/25. Check financials.
AI Summary
NRX Pharmaceuticals, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as Big Rock Partners Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector. This filing was made on April 30, 2025.
Why It Matters
This amendment provides updated financial and operational information for NRX Pharmaceuticals, crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company filing an annual report amendment, there's inherent risk related to clinical trial outcomes, regulatory approvals, and financial performance.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the annual report.)
- 10-K/A — Filing Type (Indicates an amendment to the annual report.)
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Filer of the 10-K/A
- Big Rock Partners Acquisition Corp. (company) — Former name of NRX Pharmaceuticals, Inc.
- December 31, 2024 (date) — Fiscal year end for the report
- April 30, 2025 (date) — Filing date of the amendment
- 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 (address) — Business and mailing address
FAQ
What specific information is being amended in this 10-K filing?
The provided text does not specify the exact details of the amendment, only that it is an amendment to the annual report for the fiscal year ended December 31, 2024.
When was the original 10-K filed?
The filing date for this amendment (10-K/A) is April 30, 2025. The original filing date is not explicitly stated in this excerpt.
What is the primary business of NRX Pharmaceuticals, Inc.?
NRX Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.
What was NRX Pharmaceuticals, Inc. previously named?
The company was formerly known as Big Rock Partners Acquisition Corp.
Where is NRX Pharmaceuticals, Inc. headquartered?
The company's business and mailing address is 1201 Orange Street, Suite 600, Wilmington, DE 19801.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding NRX Pharmaceuticals, Inc. (NRXPW).